Cargando…
Does tirofiban prevent platelet loss in patients after cardiogenic shock during continuous renal replacement therapy?
Link and colleagues present a pilot study investigating platelet function and platelet numbers in patients with cardiogenic shock and acute kidney failure undergoing continuous venovenous haemodialysis. Their data indicate a significantly reduced platelet loss with combined therapy of unfractionated...
Autores principales: | Storm, Christian, Jörres, Achim |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646330/ https://www.ncbi.nlm.nih.gov/pubmed/19040776 http://dx.doi.org/10.1186/cc7083 |
Ejemplares similares
-
Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study
por: Link, Andreas, et al.
Publicado: (2008) -
Microcirculation in cardiogenic shock: from scientific bystander to therapy target
por: Jung, Christian, et al.
Publicado: (2010) -
Searching for an ideal hemodynamic marker to predict short-term outcome in cardiogenic shock
por: Yilmaz, Mehmet Birhan, et al.
Publicado: (2009) -
Acute Renal Replacement Therapy
por: Jörres, Achim, et al.
Publicado: (2011) -
Renal replacement therapy for critically ill patients: an intermittent continuity
por: Ricci, Zaccaria, et al.
Publicado: (2014)